Healthcare provider profile · identity verified

Alan Glen Swartz, APRN BC

Nurse Practitioner · EVANSVILLE, IN · NPI 1689625071

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	326	82
Amlodipine Besylate	Amlodipine Besylate	288	91
Lisinopril	Lisinopril	257	64
Omeprazole	Omeprazole	245	59
Albuterol Sulfate Hfa	Albuterol Sulfate	231	71
Gabapentin	Gabapentin	207	51
Simvastatin	Simvastatin	204	51
Levothyroxine Sodium	Levothyroxine Sodium	146	40
Metformin Hcl	Metformin Hcl	136	34
Hydrochlorothiazide	Hydrochlorothiazide	128	32
Metoprolol Tartrate	Metoprolol Tartrate	125	29
Trazodone Hcl	Trazodone Hcl	119	26
Fluticasone Propionate	Fluticasone Propionate	118	39
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	107	25
Atenolol	Atenolol	105	24
Ezetimibe	Ezetimibe	97	25
Fenofibrate	Fenofibrate	92	30
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	89	22
Naproxen	Naproxen	87	33
Tamsulosin Hcl	Tamsulosin Hcl	87	24
Citalopram Hbr	Citalopram Hydrobromide	68	20
Alendronate Sodium	Alendronate Sodium	67	19
Topiramate	Topiramate	66	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	64	17
Pregabalin	Pregabalin	63	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	63	13
Potassium Chloride	Potassium Chloride	61	17
Duloxetine Hcl	Duloxetine Hcl	60	13
Losartan Potassium	Losartan Potassium	59	21
Pantoprazole Sodium	Pantoprazole Sodium	58	16
Glipizide	Glipizide	56	14
Spironolactone	Spironolactone	51	16
Tradjenta	Linagliptin	50	suppressed
Clonidine Hcl	Clonidine Hcl	45	15
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	44	14
Furosemide	Furosemide	42	17
Oxybutynin Chloride	Oxybutynin Chloride	41	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	39	suppressed
Levetiracetam	Levetiracetam	39	suppressed
Pravastatin Sodium	Pravastatin Sodium	37	suppressed
Allopurinol	Allopurinol	36	12
Clopidogrel	Clopidogrel Bisulfate	36	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	36	suppressed
Sertraline Hcl	Sertraline Hcl	34	suppressed
Bupropion Hcl	Bupropion Hcl	33	suppressed
Buspirone Hcl	Buspirone Hcl	33	11
Clonidine	Clonidine	33	suppressed
Montelukast Sodium	Montelukast Sodium	33	11
Carvedilol	Carvedilol	32	14
Clonazepam	Clonazepam	32	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	32	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	32	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	31	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	30	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	30	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	28	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	28	suppressed
Famotidine	Famotidine	28	13
Ibuprofen	Ibuprofen	28	11
Myrbetriq	Mirabegron	28	suppressed
Nystatin	Nystatin	28	18
Breo Ellipta	Fluticasone/Vilanterol	27	suppressed
Hydralazine Hcl	Hydralazine Hcl	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Dexlansoprazole Dr	Dexlansoprazole	25	suppressed
Meloxicam	Meloxicam	25	suppressed
Acyclovir	Acyclovir	24	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	13
Eliquis	Apixaban	23	suppressed
Januvia	Sitagliptin Phosphate	23	suppressed
Metoprolol Succinate	Metoprolol Succinate	23	12
Ventolin Hfa	Albuterol Sulfate	23	suppressed
Glipizide Er	Glipizide	22	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	22	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	21	suppressed
Lidocaine	Lidocaine	21	suppressed
Spiriva Respimat	Tiotropium Bromide	21	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	20	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	20	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	19	suppressed
Ozempic	Semaglutide	19	suppressed
Cephalexin	Cephalexin	18	suppressed
Spiriva Handihaler	Tiotropium Bromide	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Nebivolol Hcl	Nebivolol Hcl	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	17	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	16	15
Prednisone	Prednisone	16	12
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	16	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	16	suppressed
Baclofen	Baclofen	15	suppressed
Celecoxib	Celecoxib	14	suppressed
Doxepin Hcl	Doxepin Hcl	14	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	14	suppressed
Novolog Flexpen	Insulin Aspart	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	14
Testosterone Cypionate	Testosterone Cypionate	14	suppressed
Aripiprazole	Aripiprazole	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	13	12
Mirtazapine	Mirtazapine	13	suppressed
Niacin Er	Niacin	13	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Lansoprazole	Lansoprazole	12	suppressed
Linzess	Linaclotide	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Tramadol Hcl	Tramadol Hcl	12	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	11	suppressed
Jardiance	Empagliflozin	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Pure Comfort Alcohol Pad	Alcohol Antiseptic Pads	11	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error